Overview of Dr. Jiang
Dr. Yixing Jiang is an oncologist in Baltimore, MD and is affiliated with multiple hospitals in the area, including University of Maryland Medical Center and Veterans Affairs Maryland Health Care System-Baltimore Division. She received her medical degree from Shanghai Medical University and has been in practice 27 years. Dr. Jiang accepts several types of health insurance, listed below. She is one of 102 doctors at University of Maryland Medical Center and one of 25 doctors at Veterans Affairs Maryland Health Care System-Baltimore Division who specialize in Oncology. She has more than 60 publications and over 500 citings.
Office
22 S Greene St
Baltimore, MD 21201Fax+1 410-328-6896
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2002 - 2005
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1999 - 2002
Shanghai Medical UniversityClass of 1990
Certifications & Licensure
MD State Medical License 2012 - 2026
TX State Medical License 2003 - 2026
PA State Medical License 2005 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Start of enrollment: 2006 Sep 15
- Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer Start of enrollment: 2007 Dec 01
- Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2012 May 15
- Join now to see all
Publications & Presentations
PubMed
- DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma.Allison M Kirk, Jeremy Chase Crawford, Ching-Heng Chou, Cliff Guy, Kirti Pandey
Cell Reports. Medicine. 2024-03-19 - 1 citationsPhase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort.Oluwadunni E Emiloju, Jun Yin, Emily Koubek, Joel M Reid, Mitesh J Borad
Investigational New Drugs. 2024-02-01 - 5 citationsA phase I study of the ceramide nanoliposome in patients with advanced solid tumors.Aaron Ciner, Theodore Gourdin, Jeff Davidson, Mylisa Parette, Susan J Walker
Cancer Chemotherapy and Pharmacology. 2024-01-01
Press Mentions
Lower Gastrointestinal Neuroendocrine Neoplasms Associated with Hereditary Cancer Syndromes: A Case SeriesJuly 22nd, 2020
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
Anthem Blue Preferred Plus POS
BCBS Blue Card PPO
BCBS Illinois PPO
BCBS Texas BlueChoice
Capital BC Keystone Health Plan Central HMO
Capital Blue Cross PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPOCofinity PPO
First Health PPO
Great West PPO
Highmark BCBS ClassicBlue
Highmark BCBS PPOBlue
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
Network Health Plan HMO
Network Health Plan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
WEA Trust Preferred Provider Plan - Trust Pref - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
